title: Influence of endogenous neuropeptide Y (NPY) on the sympathetic-parasympathetic interaction in the canine heart.
abstract: The purpose of this study was to examine the sympathetic-parasympathetic interactions on heart rate through release of neuropeptide Y (NPY) and its action on prejunctional NPY Y2 receptors on vagal and sympathetic nerve fibers. In other studies on various preparations and in various organs, attenuation of transmitter release has in fact been demonstrated through activation of the NPY Y2 receptor. In the present study on anesthetized dogs we examine, however, for the first time if vagal bradycardia is attenuated by endogenous NPY released during intense cardiac sympathetic stimulation. In addition, we explore if sympathetic transmitter release and heart rate, during moderate sympathetic stimulation, are affected through this receptor system. The significance of the NPY Y2 receptor was revealed by performing experiments before and after administration of its specific receptor antagonist BIIE0246. We found that attenuation of the bradycardia during vagal nerve stimulation was dose-dependently counteracted by BIIE0246 and that the tachycardia elicited by sympathetic stimulation remained unaffected after NPY Y2 receptor blockade. Thus, endogenous NPY appears to attenuate vagal bradycardia by stimulating prejunctional NPY Y2 receptors on cardiac vagal nerve terminals and, less efficiently, to attenuate transmitter release and tachycardia through a feedback loop on the cardiac sympathetic nerve fibers.
authors.affiliation: Institute for Experimental Medical Research, Ullevål University Hospital, 0407 Oslo, Norway. arnfinn.ilebekk@medisin.uio.no
authors.forename: Arnfinn
authors.initials: A
authors.lastname: Ilebekk
authors.forename: Jan-Arne
authors.initials: JA
authors.lastname: Björkman
authors.forename: Margareta
authors.initials: M
authors.lastname: Nordlander
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D001794:Blood Pressure / Q000502:physiology; D002395:Catecholamines / Q000378:metabolism; D004285:Dogs; D004558:Electric Stimulation; D006321:Heart / Q000294:innervation / Q000502:physiology*; D006339:Heart Rate / Q000502:physiology; D009206:Myocardium / Q000378:metabolism; D009412:Nerve Fibers / Q000502:physiology; D009478:Neuropeptide Y / Q000378:metabolism*; D010275:Parasympathetic Nervous System / Q000502:physiology*; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000502:physiology*; D013997:Time Factors; D014630:Vagus Nerve / Q000502:physiology
chemical_list: D001552:Benzazepines; D002395:Catecholamines; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor; D001120:Arginine; C403256:BIIE 0246